Break Wave
Phase 3- Indications
- Kidney stones
Company intelligence / Profile preview
SonoMotion’s Stone Clear™ device received FDA de novo clearance in October 2024 as the first and only noninvasive ultrasound device to facilitate passage of post-lithotripsy kidney stone fragments without anesthesia. Clinical data show a 70% reduction in relapse risk compared to observation. The Break Wave™ system, designed to fragment intact kidney stones using low-pressure ultrasound waves in awake patients without anesthesia, has completed pivotal clinical trials with results supporting an upcoming FDA 510(k) submission[2][3][4][6].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SonoMotion.